Cheng Pei-Wen, Liang Hsin-Li, Lin Hui-Li, Hao Chi-Long, Tseng Yu-Hsiu, Tu Yi-Chen, Yeh Bor-Chun, Shen Kuo-Ping
Department of Medical Education and Research, Kaohsiung Veterans General Hospital, No. 386, Dazhong 1st Rd., Zuoying Dist., Kaohsiung City 813414, Taiwan.
Institute of Biomedical Sciences, National Sun Yat-Sen University, No. 70, Lien-hai Rd., Kaohsiung City 804, Taiwan.
J Clin Biochem Nutr. 2022 May;70(3):248-255. doi: 10.3164/jcbn.21-158. Epub 2022 Mar 24.
In past researches, we had been proved the action mechanism of pre-germinated brown rice (PGBR) to treat metabolic syndrome and diabetes mellitus. This study was to investigate the protective effect of PGBR in high fructose and high fat-induced non-alcoholic fatty liver disease (NAFLD) in rodents. WKY rats were divided into: Control group was fed normal drinking water and diet; FLD group was fed 10% high-fructose-water (HFW) and high-fat-diet (HFD); PGBR group was given HFW, and HFD mixed PGBR. After four weeks, the body, hepatic and cardiac weight gains of FLD group had significant increases than that of Control group. The enhanced blood pressure and heart rate, hypertriglyceridemia, hyperuricemia, and higher liver function index (GPT levels) were observed; meanwhile, the IL-6 and TNF-α levels of serum, and TG level of liver were also elevated in FLD group. The related protein expressions of lipid synthesis, inflammation, cardiac fibrosis, and hypertrophy were deteriorated by HFW/HFD. However, in treatment group, PGBR decreased all above influenced parameters, additionally GOT; and related protein expressions. PGBR treated HFW/HFD-induced NAFLD and cardiac complications might be via improving lipid homeostasis, and inhibiting inflammation. Together, PGBR could be used as a healthy food for controlling NAFLD and its' cardiac dysfunction.
在以往的研究中，我们已经证实了发芽糙米（PGBR）治疗代谢综合征和糖尿病的作用机制。本研究旨在探讨PGBR对高果糖和高脂肪诱导的啮齿动物非酒精性脂肪性肝病（NAFLD）的保护作用。WKY大鼠被分为：对照组给予正常饮用水和饮食；脂肪肝组给予10%高果糖水（HFW）和高脂肪饮食（HFD）；PGBR组给予HFW和混合了PGBR的HFD。四周后，脂肪肝组的体重、肝脏和心脏增重显著高于对照组。观察到血压和心率升高、高甘油三酯血症、高尿酸血症以及肝功能指标（GPT水平）升高；同时，脂肪肝组血清IL-6和TNF-α水平以及肝脏TG水平也升高。HFW/HFD使脂质合成、炎症、心脏纤维化和肥大的相关蛋白表达恶化。然而，在治疗组中，PGBR降低了上述所有受影响的参数，另外还有GOT以及相关蛋白表达。PGBR治疗HFW/HFD诱导的NAFLD和心脏并发症可能是通过改善脂质稳态和抑制炎症来实现的。总之，PGBR可作为一种控制NAFLD及其心脏功能障碍的健康食品。
